David Adair

Council for Entrepreneurial Development provides an interactive forum for entrepreneurs, investors, service professionals, academicians, researchers and public policy makers. Its services and programs include connections to capital, venture mentoring, and signature conferences empower member companies to go further. The company was founded in 1984 and is headquartered in Durham, NC.

Rex Health Ventures LLC (Rex Health Ventures) is a venture capital subsidiary of Rex Strategic Innovations founded in 2012. The firm is headquartered in Raleigh, North Carolina.

Vascular Pharmaceuticals, Inc. develops and commercializes therapeutics for the treatment of diabetics. It provides new treatment options to individuals living with diabetic complications such as nephropathy. The company was founded by David R. Clemmons and Laura Maile in 2005 and is headquartered in Research Triangle Park, NC.

KCBN Holding, Inc. provides compliance services to the healthcare sector. The company is headquartered in Kansas City, MO.

Evolution Research Group LLC provides in-patient and out-patient clinical trial services to pharmaceutical companies. It specializes in psychiatric and neurological disorders, sleep disorders, addictions, acute and chronic pain, renal insufficiency and hepatic impairment, and normal healthy volunteers. The company was founded in 2014 and is headquartered in New Providence, NJ.

Advarra, Inc. engages in the provision of integrated research compliance solutions. It offers institutional review board (IRB), institutional biosafety committee (IBC), and research quality and compliance consulting services. It also covers GxP/GCP auditing and compliance, regulatory, clinical quality and assurance, research administration and human research protection (HRP), and data protection and technology compliance. The company was founded in 1983 and is headquartered in Columbia, MD.

Basking Biosciences, Inc. is a clinical-stage company that aims to solve the biggest need in ischemic stroke therapy. The company is based in Columbus, OH. The company is developing a first-in-class RNA aptamer targeting von Willebrand factor (vWF), an important structural component of blood clots and driver of the clotting process. Basking is also developing a complementary rapid-acting reversal oligonucleotide capable of quickly neutralizing the pharmacological activity of the RNA aptamer. The company has successfully completed a phase 1 single-ascending dose safety study and is initiating a phase 2 clinical proof-of-concept study in patients suffering from an acute ischemic stroke. The ultimate goal is to extend the therapeutic window for thrombolysis compared to currently approved therapies. Basking Biosciences was founded in 2019 by Shahid Nimjee, Bruce A. Sullenger, and Richard J. Shea has been the CEO of the company since 2019.

Mitochem Therapeutics, Inc. is a privately held company based in Charleston, SC that develops therapies for diseases involving mitochondrial dysfunction. Mitochem Therapeutics has a proprietary library of mitochondrial protective compounds, and early proof of concept in numerous in vivo models for retinitis pigmentosa (RP) and age-related macular degeneration (AMD). The lead compound MC16 is a first-in-class small molecule that up-regulates pro-survival and anti-oxidant pathways. In 2021, the Food and Drug Administration (FDA) granted orphan drug designation status to MC16 for the treatment of RP. The company is pursuing partnerships to develop non-ophthalmic indications such as Parkinson's, Alzheimer's, ALS, muscular dystrophies, diabetes, ischemias, and kidney diseases. The company was founded by Bärbel Rohrer and Craig C. Beeson to develop a new approach to treating neurodegeneration and aging diseases by protecting mitochondrial homeostasis. The CEO is Michael Voevodsky.